EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of Novel Small-Molecule Targeting SCN1A-Associated Severe Myoclonic Epilepsy of Infancy

Dong Gun Kim, Kyu-Seok Hwang iD, Se Hwan Ahn, Seong Soon Kim iD, Yuji Son, Sung Bum Park, Won Hoon Jung, Dae-Seop Shin, Sung Hee Cho, Byeong Wook Choi iD, Pyeongkeun Kim iD, Yerim Heo und 9 weitere

Journal of Medicinal Chemistry · 12.02.2026 · 69 (3) · 3362-3377

DOI: 10.1021/acs.jmedchem.5c03293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 23.01.2026. Verfasst von Dong Gun Kim und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea. Hauptthemen laut MEDLINE: Epilepsies, Myoclonic, Anticonvulsants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute, Korea Research Institute of Chemical Technology, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe myoclonic epilepsy of infancy (SMEI, Dravet syndrome), which is mainly caused by the SCN1A mutation, is a severe epileptic encephalopathy that manifests in infancy and leads to intractable seizures and developmental impairment. To discover new therapeutic chemotypes, we established a Nav1.1 (scn1lab) KO zebrafish model for chemical screening and identified novel 1,3,4-oxadiazol-2(3H)-one derivatives. Among them, compound 20e showed the most potent antiseizure efficacy in zebrafish behavioral assays and significantly reduced locomotion-related seizure parameters compared with repositioned drugs. In SCN1A+/- mice, 20e reduced seizure severity, delayed onset, and suppressed hyperactivity. Notably, 20e normalized pathological spike and burst activity in SMEI patient-derived iPSC neurons. Mechanistically, 20e appears to elevate 5-HT levels via TPH2 upregulation. It demonstrated reasonable BBB penetration, favorable oral PK, and good safety without notable hERG inhibition, cytotoxicity, mutagenicity, or acute toxicity. Taken together, compound 20e shows promise as a therapeutic agent for SMEI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epilepsies, MyoclonicAnticonvulsantsHumansAnimalsNAV1.1 Voltage-Gated Sodium ChannelZebrafishMiceStructure-Activity Relationship

Substanzen

NAV1.1 Voltage-Gated Sodium ChannelAnticonvulsantsSCN1A protein, human

Autor:innen und Institutionen

  • Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea.
  • Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
  • Department of Medical Chemistry and Pharmacology, University of Science & Technology, Daejeon 34113, Republic of Korea.
  • Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology, Ochang 28116, Republic of Korea.
  • Center for Biomimetic Research, Korea Institute of Toxicology, Daejeon 34114, Republic of Korea.
  • Division of Pediatric Neurology, Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Epilepsy Research Institute, Seoul 03722, Republic of Korea.

ORCID-Profile: Kyu-Seok Hwang, Seong Soon Kim, Byeong Wook Choi, Pyeongkeun Kim, Kyeong-Ryoon Lee, Hyang-Ae Lee, Jin Hee Ahn

Förderung

  • Korea Health Industry Development Institute
  • Korea Research Institute of Chemical Technology
  • National Research Foundation of Korea
  • Ministry of Trade, Industry and Energy

Zitieren

APA

Kim, D. G., Hwang, K. S., Ahn, S. H., Kim, S. S., Son, Y., Park, S. B., Jung, W. H., Shin, D. S., Cho, S. H., Choi, B. W., Kim, P., Heo, Y., Kim, M., Yang, J. Y., Lee, K. R., Lee, H. A., Kim, J., Kang, H. C., Kim, K. Y., …, & Ahn, J. H. (2026). Development of Novel Small-Molecule Targeting SCN1A-Associated Severe Myoclonic Epilepsy of Infancy. Journal of Medicinal Chemistry, 69(3), 3362-3377. https://doi.org/10.1021/acs.jmedchem.5c03293

Vancouver

Kim DG, Hwang KS, Ahn SH, Kim SS, Son Y, Park SB, et al. Development of Novel Small-Molecule Targeting SCN1A-Associated Severe Myoclonic Epilepsy of Infancy. Journal of Medicinal Chemistry. 2026;69(3):3362-3377. doi:10.1021/acs.jmedchem.5c03293

BibTeX
@article{Kim2026,
  author = {Kim, Dong Gun and Hwang, Kyu-Seok and Ahn, Se Hwan and Kim, Seong Soon and Son, Yuji and Park, Sung Bum and Jung, Won Hoon and Shin, Dae-Seop and Cho, Sung Hee and Choi, Byeong Wook and Kim, Pyeongkeun and Heo, Yerim and Kim, Minhee and Yang, Jung Yoon and Lee, Kyeong-Ryoon and Lee, Hyang-Ae and Kim, Jihun and Kang, Hoon-Chul and Kim, Ki Young and Bae, Myung Ae and Ahn, Jin Hee},
  title = {Development of Novel Small-Molecule Targeting SCN1A-Associated Severe Myoclonic Epilepsy of Infancy},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {3},
  pages = {3362--3377},
  doi = {10.1021/acs.jmedchem.5c03293}
}
Kostenlos starten →